伊马替尼治疗慢性期慢性髓细胞白血病早期分子反应39例临床分析  

Clinical analysis of early molecular response of 39 cases of chronic myeloid leukemia in chronic phase treated with imatinib

作　　者：刘景华[1] 周凡[1] 刘洋[1] 惠玉[1] 刘彦琴[1] 王吉刚[1] 白颖[1] 张晓琳[1] 李敏燕[1] 

机构地区：[1]沈阳军区总医院血液内科,辽宁沈阳110016

出　　处：《临床军医杂志》2015年第12期1215-1217,共3页Clinical Journal of Medical Officers

基　　金：辽宁省科技攻关课题(2013225089);辽宁省科技计划课题(2011225021)

摘　　要：目的：评估伊马替尼治疗慢性期慢性髓细胞白血病（ CML）的早期分子反应（EMR）。方法回顾性分析我院自2011年4月至2014年3月应用伊马替尼治疗的39例 CML 慢性期 EMR 的患者，并分析影响 EMR 的因素。结果39例 CML患者可评估38例，EMR 率61%。其中，低、中危组 EMR 率70%（19/27），高危组 EMR 率36%（4/11）。高危组与中、低组比较，EMR 率明显减低（P 〈0.05）。EMR 患者和 EMR 失败患者，例数分别为23例和15例；初诊时肋缘下脾脏大小分别为4.0（QR =1.5）cm，11.3（QR =1.6）cm（P 〈0.05）；白细胞计数分别为23（QR =4.0）×10^9/ L，35（QR =8.9）×10^9/ L（P 〈0.05）。结论初诊时脾脏大、白细胞计数高、Soka1评分高危可能与伊马替尼治疗 CML 的 EMR 失败相关。Objective To assess the ear1y mo1ecu1ar response（ EMR）of imatinibin the treatment of Chronic mye1oid 1eukemia inchronic phase. Methods From Apri1 2011 to March 2014,tota11y 39 diagnosed chronic mye1oid 1eukemia inchronic phase were ana-1yzed and ana1yzed EMR and inf1uentia1 factor. Results Among 39 cases assessed,tota1 EMR rate was 61% ;and 1ow risk and inter-mediate risk groups,high risk groups were 70% and 36% ,respective1y. Patients with EMR and without EMR were 23 cases and 15 ca-ses,respective1y. Median sp1een size be1ow costa1 margin were 4. 0（QR = 1. 5）cm and 11. 3（QR = 1. 6）cm,respective1y. Median white ce11 count were 23（QR = 4. 0）× 10^9 / L and 35（QR = 8. 9）× 10^9 / L,respective1y. Conclusion Sp1enomega1y,high white ce11 count and Soka1 high risk are possib1e re1ative to EMR fai1ure of imatinib in the treatment of chronic mye1oid 1eukemia inchronic phase.

关 键 词：慢性髓细胞白血病 伊马替尼 早期分子反应 

分 类 号：R733[医药卫生—肿瘤]